The Myelin Repair Foundation Enters First International Partnership with Bionure, Inc.
PRESS RELEASE. OCTOBER 31, 2013.
Bionure, Inc. and Myelin Repair Foundation Collaboration to Advance Neuroprotective Multiple Sclerosis (MS) Therapeutic BN201 Towards Commercialization. In this agreement, the Myelin Repair Foundation will work closely with Bionure, Inc. to assess the neuroprotective capabilities that will promote myelin repair of the company’s proprietary MS therapeutic compound, BN201. BN201 is a potential MS treatment for acute optic neuritis and severe MS relapses.